Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 0%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc has demonstrated a significant increase in demand for its NeXT Personal diagnostic test, with a 41% quarter-over-quarter rise in volumes in Q4'25, strongly supported by its partnership with Tempus, which is expected to enhance marketing efforts. Additionally, the recent announcement of Medicare coverage for the NeXT Personal MRD test in breast cancer represents a pivotal milestone, further enhancing the test's market accessibility and potential for revenue growth. The company's ability to detect minimal residual disease (MRD) with high sensitivity in the 1-100ppm range, along with a strategic approach to managing cash burn during the reimbursement process, suggests a solid foundation for sustainable growth and an undervaluation relative to market potential.

Bears say

Personalis Inc. is facing a challenging financial landscape, as evidenced by its lowered revenue guidance for 2025, now projected at $68 million to $73 million, reflecting a year-over-year decline of 12% to 5%. Additionally, the company has encountered logistical issues with global samples and a broader slowdown in the biopharma sector, which could adversely impact demand for its sequencing and data analysis services. Furthermore, despite raising $109 million in net proceeds from its ATM facility in Q4'25, the overall financial stability remains under threat due to significant losses and ongoing concerns regarding profitability and revenue generation.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 0% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.